159 related articles for article (PubMed ID: 24384589)
1. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
Gutiérrez C; Hernández-Novoa B; Vallejo A; Serrano-Villar S; Abad-Fernández M; Madrid N; Díaz L; Moreno A; Dronda F; Zamora J; Muñoz-Fernández MA; Moreno S
AIDS; 2013 Aug; 27(13):2081-8. PubMed ID: 24384589
[TBL] [Abstract][Full Text] [Related]
2. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
[TBL] [Abstract][Full Text] [Related]
3. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
4. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
5. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
6. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
7. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
8. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Massanella M; Esteve A; Buzón MJ; Llibre JM; Puertas MC; Gatell JM; Domingo P; Stevenson M; Clotet B; Martinez-Picado J; Blanco J;
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):152-60. PubMed ID: 23392458
[TBL] [Abstract][Full Text] [Related]
11. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.
Serrano-Villar S; Gutiérrez C; Vallejo A; Hernández-Novoa B; Díaz L; Abad Fernández M; Madrid N; Dronda F; Zamora J; Muñoz-Fernández MÁ; Moreno S
J Infect; 2013 Jan; 66(1):57-66. PubMed ID: 23046968
[TBL] [Abstract][Full Text] [Related]
12. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
[TBL] [Abstract][Full Text] [Related]
13. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
Negredo E; Massanella M; Puertas MC; Buzón MJ; Puig J; Pérez-Alvárez N; Pérez-Santiago J; Bonjoch A; Moltó J; Jou A; Echeverría P; Llibre JM; Martínez-Picado J; Clotet B; Blanco J
J Antimicrob Chemother; 2013 Oct; 68(10):2358-62. PubMed ID: 23677919
[TBL] [Abstract][Full Text] [Related]
14. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
15. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
[TBL] [Abstract][Full Text] [Related]
16. Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.
Pallikkuth S; Sharkey M; Babic DZ; Gupta S; Stone GW; Fischl MA; Stevenson M; Pahwa S
J Virol; 2015 Dec; 90(6):2718-28. PubMed ID: 26676775
[TBL] [Abstract][Full Text] [Related]
17. CD161
Li X; Liu Z; Li Q; Hu R; Zhao L; Yang Y; Zhao J; Huang Z; Gao H; Li L; Cai W; Deng K
mBio; 2019 Oct; 10(5):. PubMed ID: 31594817
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
[TBL] [Abstract][Full Text] [Related]
19. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Gianotti N; Spagnuolo V; Carbone A; Chiappetta S; Ripa M; Tambussi G; Lazzarin A; Castagna A
New Microbiol; 2014 Apr; 37(2):145-51. PubMed ID: 24858641
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
